RPP Group and ANSYS

James Kennedy, Associate Director RPP discusses the growing interest of policymakers for Personalized Alliance in modern medicine, their desire to accelerate the adoption of in silico clinical trials and the leading role ANSYS is playing to make this evolution a reality.

For more information read "A Healthy Future."